Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company''s product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Latest shares articles
We haven’t seen this level of market concentration since the Great Depression
If you had invested $10,000 in the equal weighted S&P 500 in 2015, you’d be sitting on just over $25,000 today.
18:54, 29 July 2025
Dogecoin price prediction 2025-2030: Third-party price target
Could dogecoin reach $1? Explore third-party DOGE price predictions and insights for 2025 and beyond.
14:50, 29 July 2025
Trading the DAX 40 following the US-EU trade deal
Weekend gap gets filled as initial euphoric move faces a bit of turbulence, in all keeping its technical overview unchanged in both daily and weekly time frames.
09:32, 28 July 2025
Bitcoin price prediction: Third-party price target
Bitcoin (BTC), the world’s first cryptocurrency, remains the largest by market capitalisation. As a decentralised digital asset, it’s widely seen as a store of value and hedge against inflation.
12:13, 27 July 2025
Ratings and Reviews
Ratings and Reviews
